Embargo Watch

Keeping an eye on how scientific information embargoes affect news coverage

FDA wants stenographers? Agency says reporters can’t interview anyone before its embargo lifts

with 2 comments

Last week, the FDA announced changes to its medical device approval process, aka 510(k) clearance, which has been the source of complaints from many in the industry. But as the embargo lifted at 1 p.m. Eastern on January 19, all you saw in the media were brief stories like this one. It took a little while before you could get any reaction from industry or other players.

Here’s why: On January 19, a few hours before the embargo lifted, the FDA’s Karen Riley, of the Office of Public Affairs, wrote the following (FYI, it was not me at Reuters asking):

Reuters is asking, so I am clarifying. It goes without saying that the embargo means YOU CANNOT call around and get comment ahead of the 1 p.m. embargo. Needless to say, that would effectively break the embargo.

Actually, it does need some saying, since this is a new version of a journalistic embargo. Cardiobrief’s Larry Husten wrote to Riley in response:

Just for future reference I strongly suggest you rethink this policy. From everything that I understand, the major purpose and best rationale for an embargo is to allow reporters to get a deeper perspective on a complex story. By necessity this often entails asking other experts in the field. Of course, these experts need to be apprised of the embargo and they need to agree to its terms.

I’m guessing you’ve heard similar points from other reporters…

As Husten notes, one of the main reasons for embargoes — at least, if you take journals at face value — is to allow for better, more informed coverage. Part of how that coverage happens is that reporters can go interview sources other than the embargoing institution.

Without that, journalists become stenographers. If that’s what the FDA — a public agency — wants, they need to rethink. And if they insist that this is what they mean by a journalistic embargo, then I’d suggest reporters stop agreeing to them. There’s really no benefit to reporters or the public, only to the FDA.

I’ve tried to reach Riley, and will update if I hear back.

About these ads

Written by Ivan Oransky

January 28, 2011 at 10:50 am

Posted in Uncategorized

2 Responses

Subscribe to comments with RSS.

  1. /headdesk

    Maryn

    January 28, 2011 at 2:26 pm

  2. Embargoes just give the journalist the opportunity to put in place the best strategy to write a good story.
    If the reporter encounters a limit in sourcing relevant comments and opinions on the issue, ahead of the news story’s release, the capacity for the media to deliver accurate, thorough and complete information will also find evident restrictions.
    With the time constraints that all the journalists are facing, competition would not allow outlets to put the news in the best context once they’re out.

    Echoing a press release is not a job a journalist is called on to execute. It’s nothing but good analysis what meets the public interest. And health is quintessentially in the public interest.

    kore.a

    January 28, 2011 at 8:13 pm


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

Follow

Get every new post delivered to your Inbox.

Join 23,209 other followers

%d bloggers like this: